Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

June 2024

A disease-associated gene desert directs macrophage inflammation through ETS2

Nature 2024 doi: 10.1038/s41586-024-07501-1 Epub ahead of print

Haag LM,

Papa I,

Zhang Q,

Zhang T,

Wood CS,

New FN,

Hall A,

Jiang L,

Saruhan-Direskeneli G,

Green M,

Nye E,

Stankey, et al. used functional genomics to show that the ETS2 gene is a central regulator of human inflammatory macrophages. They also found that ETS2 was disrupted by JAK inhibitors and MEK inhibitors, with multiple MEK inhibitors being shown to downregulate ETS2-target genes.

Keywords:

JAK,
MOA

December 2022

Évaluation de la TEV, du MACE et des infections graves chez les patients PR traités par le baricitinib par rapport au TNFi : Une étude multi-bases de données de patients en soins de routine, utilisant des registres de maladies et bases de données des réclamations

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00505-1

Bower H,

Song Y,

Bosan R,

Zhu B,

Mai X,

Deberdt W; B023 Study Consortium

Salinas, et al. evaluate baricitinib safety with respect to VTE, MACE, and serious infection relative to TNFi in patients with RA, in routine care and observe an increased risk of VTE in patients taking baricitinib, compared to TNFi.